TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00490490
Drug: Potassium Iodide (KI)
Normalized name: Potassium Iodide
DrugBank: Potassium Iodide (DB06715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium iodide (KI) will be administered as:~* Saturated solution potassium iodide (SSKI) 4 drops orally 3-times-a-day,~* Lugol's solution 20 drops orally 3-times-a-day, OR~* KI tablets 130 mg orally once per day KI treatment will start at least 24 hours prior to tositumomab, and continue daily for 14 days following the last dose of tositumomab
Study: NCT00417664
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine administered as part of anesthesia in cardiac surgery patients
Study: NCT00417664
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administered as part of anesthesia in cardiac surgery patients
Study: NCT00417664
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam administered as part of anesthesia in cardiac surgery patients
Study: NCT05148637
Drug: Maintenance of general anesthesia by Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia was maintained by inhalational anesthesia (sevoflurane) titrated by monitoring of patient sensitivity index of the Masimo
Study: NCT05148637
Drug: Maintenance of general anesthesia by Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia was maintained by inhalational anesthesia (desflurane) titrated by monitoring of patient sensitivity index of the Masimo
Study: NCT03483259
Drug: Sulfatinib T capsule
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfatinib T capsules were produced by Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd. production.
Study: NCT02589145
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose Escalation Phase Starting dose of Lenalidomide: 50 mg by mouth on Days -9 to -2.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Phase I.
Study: NCT02589145
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 mg by mouth on Days -9 to -2.
Study: NCT02589145
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine administered as a loading dose of 75 mg/m2 by vein on Day -8 and 2775 mg by vein on Day -3.
Study: NCT02589145
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan test dose administered by vein either as outpatient before admission, or as inpatient on day -10. The test dose of 32 mg/m2 based on actual body weight. Doses of days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1.
Study: NCT02589145
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2 by vein on days -3 and -2.
Study: NCT02589145
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with CD20+ tumors receive Rituximab 375 mg/m2 by vein on day -9 in the AM as an inpatient.
Study: NCT02589145
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8 mg by vein twice a day from Day -8 AM to Day -2 PM.
Study: NCT02589145
Drug: Glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
Study: NCT02589145
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg subcutaneously daily from admission until platelet count drops below 50,000/mm3.
Study: NCT01423864
Drug: conventional ECMO with intravenous steroid
Normalized name: Primatene with ephedrine Pill
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome treated with intravenous steroid, Solu-Cortef 50mg q6h taper down when hemodynamic stable
Study: NCT02589145
Drug: Palifermin
Normalized name: palifermin
DrugBank: Palifermin (DB00039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Palifermin per departmental standard of care with 3 doses to be administered prior to starting chemotherapy and 3 doses starting on day 0.
Study: NCT06517433
Drug: upifitamab rilsodotin
Normalized name: Upinitatug rilsodotin
DrugBank: Upinitatug rilsodotin (DB19104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536
Study: NCT01673178
Drug: 25 mg PF-05231023
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 mg IV once a week for 4 weeks
Study: NCT00250822
Drug: Gemcitabine and Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose:~Gemcitabine 1000 mg/m2 - IV in about 60 minutes on days 1 \& 15. Oxaliplatin 100 mg/m2 - IV over 2hr on days 2 \& 16
Study: NCT00004102
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00402727
Drug: Moxifloxacin (Avelox, BAY12-8039)
Normalized name: moxifloxacin Injection [Avelox]
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not always mandatory.
Study: NCT00402727
Drug: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
Study: NCT00088205
Drug: enzastaurin
Normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 milligrams (mg), oral, daily, up to six 28-day cycles
Study: NCT00510614
Drug: tinidazole
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 gram twice weekly for 12 weeks
Study: NCT02819570
Drug: I.V cefuroxime 750 mg*3/d for 2 days
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02819570
Drug: I.V ampicillin 2 gram x4/d for 2 days
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02819570
Drug: P.O cefuroxime 500 mgx2/d for 5 days
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01859182
Drug: selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01859182
Drug: Akt inhibitor MK2206
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04297202
Drug: Apatinib Combined With SHR-1210 Injection
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 cycles of neoadjuvant therapy before surgery, two weeks is a treatment cycle: D1、D15、D31 : SHR-1210 200mg, I.V, q2w； D1-D20 : Apatinib 250 mg, orally, qd; D46 : Patients were preoperatively evaluated. Operable patients were scheduled for hepatectomy with/without microwave ablation; After 4 to 8 weeks after liver resection, a postoperative adjuvant program is performed. Three weeks is a treatment cycle with a total of 8 cycles~In each cycle:~D1: SHR-1210 200mg, I.V, q3w; D1-D21: Apatinib 250mg, orally, qd;
Study: NCT03528551
Drug: Turoctocog alfa pegol
Normalized name: Turoctocog alfa pegol
DrugBank: Turoctocog alfa pegol (DB14738)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Turoctocog alfa pegol 75 IU/kg body weight will be administered once weekly as intravenous injections for a duration of 2 years.
Study: NCT03241108
Drug: NI-0101
Normalized name: Toto ni vavalagi oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humanized immunoglobulin gamma 1 (IgG1) kappa monoclonal antibody targeting TLR4
Study: NCT03528551
Drug: Turoctocog alfa pegol
Normalized name: Turoctocog alfa pegol
DrugBank: Turoctocog alfa pegol (DB14738)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Turoctocog alfa pegol 60 IU/kg body weight (for patients younger than 12 years) and 50 IU/kg body weight (for patients, 12 years or older) will be administered twice weekly as intravenous injections for a duration of 2 years.
Study: NCT03528551
Drug: Turoctocog alfa pegol
Normalized name: Turoctocog alfa pegol
DrugBank: Turoctocog alfa pegol (DB14738)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Turoctocog alfa pegol 50 IU/kg body weight will be administered three times weekly as intravenous injections for a duration of 2 years.
Study: NCT00808067
Drug: dabigatran dose 1
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dabigatran high dose twice daily
Study: NCT00436852
Drug: ABT-751
Normalized name: ABT-751
DrugBank: ABT-751 (DB12254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT00808067
Drug: dabigatran dose 2
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dabigatran low dose twice daily
Study: NCT02141620
Drug: Cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and n-acetylcysteine.
Study: NCT02141620
Drug: n-Acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004487
Drug: chondrocyte-alginate gel suspension
Normalized name: alginic acid / cimetidine Oral Suspension
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01767571
Drug: Cephalexin 125 mg/5ml
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product 20 ml
Study: NCT01767571
Drug: Cephalexin 250mg/5ml
Normalized name: CEPHALEXIN 250MG/5ML SUSP
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product 10 ml
Study: NCT04028115
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Scheduled visits: Patients included in the trial will be treated with Ixazomib 4 mg on day 1, 8, and 15 in a 28-day cycle for up to 24 cycles. Patients will be evaluated every 4th week by a medical doctor, prior to initiation of a new cycle of Ixazomib.
Study: NCT00144430
Drug: Pentostatin
Normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The drug, Pentostatin, is given every 2 weeks. This drug will be given by intravenous (IV) infusion.
Study: NCT03971383
Drug: Aolanti Weipang Tablets
Normalized name: Atlantic mackerel
DrugBank: Atlantic mackerel (DB15542)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets one time, 3 times a day(tid)
Study: NCT00961480
Drug: sitagliptin phosphate (+) metformin hydrochloride
Normalized name: metformin / sitagliptin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: place holder - do not post
Study: NCT00961480
Drug: Comparator: metformin 500mg
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single dose of metformin 500 mg tablet
Study: NCT00961480
Drug: Comparator: sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single dose of 50 mg sitagliptin tablet
Study: NCT00961480
Drug: Comparator: FMI sitagliptin / metformin 50 mg/500 mg FDC tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet
Study: NCT00018642
Drug: quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00018642
Drug: haloperidol decanoate
Normalized name: Haloperidol Decanoate
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02563834
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline infusion for control
Study: NCT02563834
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin infusion for insulin/glucose clamp procedure
Study: NCT00319605
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02590055
Drug: gemcitabine/docetaxel combination
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00288652
Drug: [S,S]-Reboxetine
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00120471
Drug: Tenofovir disoproxil fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600-mg tablet taken orally once daily
Study: NCT00120471
Drug: Tenofovir disoproxil fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-mg/kg oral suspension taken at birth and on Days 3 and 5 after birth
Study: NCT00120471
Drug: Tenofovir disoproxil fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-mg/kg oral suspension taken at birth and daily for 7 days after birth
Study: NCT01061606
Drug: temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT00679484
Drug: olmesartan medoxomil + candesartan cilexetil placebo
Normalized name: Candesartan Cilexetil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage form: tablet; frequency: daily; duration: 24 weeks
Study: NCT00961480
Drug: Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
Study: NCT00961480
Drug: Comparator: FMI sitagliptin/metformin 50 mg/850 mg FDC tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single dose of FMI sitagliptin/metformin 50 mg/850 mg FDC tablet
Study: NCT00961480
Drug: Comparator: metformin 1000 mg
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single dose of metformin 1000 mg tablet
Study: NCT00961480
Drug: Comparator: metformin 850 mg
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single dose of metformin 850 mg tablet
Study: NCT00431353
Drug: Ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg/kg iv bid for 21 days
Study: NCT00431353
Drug: valganciclovir [Valcyte]
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 900mg po bid for 21 days
Study: NCT00523640
Drug: combination of gemcitabine, capecitabine, and bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: gemcitabine 1000 mg/m\^2 d1, 8, capecitabine 1000 mg (flat dose) po bid d1-14, and bevacizumab 15 mg/kg d 1, on a 21 day cycle
Study: NCT03179735
Drug: Cetylpyridinium Chloride 0.7 mg/ml
Normalized name: cetylpyridinium chloride 0.7 MG/ML
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding.
Study: NCT00679484
Drug: olmesartan medoxomil placebo + candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage form: tablets; frequency: daily; duration: 24 weeks
Study: NCT01603134
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg tablet once a day
Study: NCT01635777
Drug: Miltefosine
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg/kg/day for 12 weeks
Study: NCT01635777
Drug: Miltefosine
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg/kg/day for 8 weeks
Study: NCT01676220
Drug: HOE901-U300 (new formulation of insulin glargine)
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]).
Study: NCT02707549
Drug: balanced crystalloid solution (components: sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium chloride)
Normalized name: magnesium chloride / potassium chloride / sodium acetate / sodium chloride / sodium gluconate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02707549
Drug: 0.9% sodium chloride
Normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03212495
Drug: dexamedetomidine
DrugBank: Medetomidine (DB11428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intraarticular injection of 1µg/kg dexametomidine +18ml 0.25%bubivacaine in a total volume of 20 ml.
Study: NCT03212495
Drug: neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intraarticular injection of 0.5mg/dose neostigmine +18ml 0.25%bubivacaine in a total volume of 20 ml.
Study: NCT06444204
Drug: Rilzabrutinib
Normalized name: Rilzabrutinib
DrugBank: Rilzabrutinib (DB17709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilzabrutinib tablet administered orally
Study: NCT02996474
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
Study: NCT02996474
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will be administered at a dose of 20 mg/m\^2 by continuous intravenous infusion over 1 hour repeated daily ordinarily on days 8 through 12 and 15 through 19 of alternative cycles (ie: cycles 1, 3, 5, 7). Decitabine should be repeated every 6 weeks.
Study: NCT00879073
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Approximately 15-24 study patients will be enrolled in this Phase I trial. Study patients will receive a weekly dose of IV bendamustine with whole brain radiation therapy for 3 weeks and then receive a fourth dose of IV bendamustine one week after completion of whole brain radiation therapy. The first dose of IV bendamustine will be given when whole brain radiation is initiated.
Study: NCT01676220
Drug: Lantus (insulin glargine)
Normalized name: insulin glargine Injectable Solution [Lantus]
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
Study: NCT01310868
Drug: 5-ALA
Normalized name: 5-ALA
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-ALA is used to generate tumour specific fluorescence as an aid to surgical resection of GBM, prior to the insertion of Gliadel wafers
Study: NCT03664115
Drug: Itraconazole 200 mg
Normalized name: itraconazole 200 MG
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: itraconazole 200 mg oral tablet daily, on a 21-day cycle.
Study: NCT03834363
Drug: Morphine Retard
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine retard capsules 10 mg bid.
Study: NCT00109551
Drug: zinc sulphate dietary supplement
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00948649
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - End of Treatment 1.0mg twice daily
Study: NCT02544737
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with metastatic lesions of esophageal cancer after been treated with surgery or definitive chemoradiotherapy receiving Apatinib (850mg) daily over 4 weeks.
Study: NCT04147260
Drug: BI 730357
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT04147260
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT02700048
Drug: intra-nasal naloxone
Normalized name: naloxone Nasal Spray
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps
Study: NCT02175225
Drug: Deferoxamine Mesylate
Normalized name: Deferoxamine Mesylate
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02175225
Drug: Placebo (for Deferoxamine Mesylate)
Normalized name: Deferoxamine Mesylate
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no